Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

2019263 citationsJournal Article

Authors

The primary end point of ORR with 42 days of neoadjuvant erlotinib was not met, but the secondary end point PFS was significantly improved.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 37, Issue 25, pp. 2235-2245

Field-Weighted Citation Impact: 23.42